Have a feature idea you'd love to see implemented?
Let us know!
KALA Kala Pharmaceuticals Inc
Price (delayed)
$7.1899
Market cap
$33.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$13.76
Enterprise value
$15.73M
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery
Highlights
The EPS rose by 8% since the previous quarter
Kala Pharmaceuticals's net income has increased by 2.1% QoQ
Kala Pharmaceuticals's equity has surged by 106% QoQ but it has decreased by 22% YoY
The revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of KALA
Market
Valuations
Earnings
Shares outstanding
4.61M
Market cap
$33.13M
Enterprise value
$15.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.48
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$32.88M
EBITDA
-$32.28M
Free cash flow
-$31.04M
Per share
Balance sheet
Liquidity
EPS
-$13.76
Free cash flow per share
-$10.24
Book value per share
$4.87
Revenue per share
$0
TBVPS
$20.33
Total assets
$61.61M
Total liabilities
$47.89M
Debt
$36.8M
Equity
$13.72M
Working capital
$39.66M
Debt to equity
2.68
Current ratio
3.07
Quick ratio
2.82
Net debt/EBITDA
0.54
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-66.8%
Return on equity
-396%
Return on invested capital
-111.3%
Return on capital employed
-77.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KALA stock price
How has the Kala Pharmaceuticals stock price performed over time
Intraday
0%
1 week
30.02%
1 month
34.39%
1 year
5.42%
YTD
2.71%
QTD
26.14%
Financial performance
How have Kala Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$41.25M
Net income
-$38.72M
Gross margin
N/A
Net margin
N/A
The revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
KALA's operating income is up by 4.4% YoY
Kala Pharmaceuticals's net income has increased by 2.1% QoQ
Growth
What is Kala Pharmaceuticals's growth rate over time
Valuation
What is Kala Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 8% since the previous quarter
Kala Pharmaceuticals's equity has surged by 106% QoQ but it has decreased by 22% YoY
The price to book (P/B) is 53% lower than the 5-year quarterly average of 3.1 and 37% lower than the last 4 quarters average of 2.3
The revenue has shrunk by 100% YoY
Efficiency
How efficient is Kala Pharmaceuticals business performance
The ROIC fell by 11% QoQ
The return on equity has declined by 7% since the previous quarter
Dividends
What is KALA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KALA.
Financial health
How did Kala Pharmaceuticals financials performed over time
The total assets is 29% more than the total liabilities
KALA's current ratio has shrunk by 54% YoY and by 27% QoQ
KALA's quick ratio has plunged by 53% YoY and by 31% from the previous quarter
KALA's debt is 168% higher than its equity
Kala Pharmaceuticals's equity has surged by 106% QoQ but it has decreased by 22% YoY
The debt to equity has plunged by 51% from the previous quarter but it has grown by 40% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.